|
1
|
Paik S, Shak S, Tang G, Kim C, Baker J,
Cronin M, Baehner FL, Walker MG, Watson D, Park T, et al: A
multigene assay to predict recurrence of tamoxifen-treated,
node-negative breast cancer. N Engl J Med. 351:2817–2826. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Paik S, Tang G, Shak S, Kim C, Baker J,
Kim W, Cronin M, Baehner FL, Watson D, Bryant J, et al: Gene
expression and benefit of chemotherapy in women with node-negative,
estrogen receptor-positive breast cancer. J Clin Oncol.
24:3726–3734. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
van't Veer LJ, Dai H, van de Vijver MJ, He
YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ,
Witteveen AT, et al: Gene expression profiling predicts clinical
outcome of breast cancer. Nature. 415:530–536. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
van de Vijver MJ, He YD, van't Veer LJ,
Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C,
Marton MJ, et al: A gene-expression signature as a predictor of
survival in breast cancer. N Engl J Med. 347:1999–2009. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Naoi Y, Kishi K, Tsunashima R, Shimazu K,
Shimomura A, Maruyama N, Shimoda M, Kagara N, Baba Y, Kim SJ and
Noguchi S: Comparison of efficacy of 95-gene and 21-gene classifier
(Oncotype DX) for prediction of recurrence in ER-positive and
node-negative breast cancer patients. Breast Cancer Res Treat.
140:299–306. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Habel LA, Shak S, Jacobs MK, Capra A,
Alexander C, Pho M, Baker J, Walker M, Watson D, Hackett J, et al:
A population-based study of tumor gene expression and risk of
breast cancer death among lymph node-negative patients. Breast
Cancer Res. 8:R252006. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kim C, Tang G, Pogue-Geile KL, Costantino
JP, Baehner FL, Baker J, Cronin MT, Watson D, Shak S, Bohn OL, et
al: Estrogen receptor (ESR1) mRNA expression and benefit from
tamoxifen in the treatment and prevention of estrogen
receptor-positive breast cancer. J Clin Oncol. 29:4160–4167. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nishio M, Naoi Y, Tsunashima R, Nakauchi
C, Kagara N, Shimoda M, Shimomura A, Maruyama N, Shimazu K, Kim SJ
and Noguchi S: 72-gene classifier for predicting prognosis of
estrogen receptor-positive and node-negative breast cancer patients
using formalin-fixed, paraffin-embedded tumor tissues. Clin Breast
Cancer. 14:e73–e80. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hatzis C, Pusztai L, Valero V, Booser DJ,
Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, et
al: A genomic predictor of response and survival following
taxane-anthracycline chemotherapy for invasive breast cancer. JAMA.
305:1873–1881. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Naoi Y, Kishi K, Tanei T, Tsunashima R,
Tominaga N, Baba Y, Kim SJ, Taguchi T, Tamaki Y and Noguchi S:
Development of 95-gene classifier as a powerful predictor of
recurrences in node-negative and ER-positive breast cancer
patients. Breast Cancer Res Treat. 128:633–641. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sota Y, Naoi Y, Tsunashima R, Kagara N,
Shimazu K, Maruyama N, Shimomura A, Shimoda M, Kishi K, Baba Y, et
al: Construction of novel immune-related signature for prediction
of pathological complete response to neoadjuvant chemotherapy in
human breast cancer. Ann Oncol. 25:100–106. 2013. View Article : Google Scholar
|
|
12
|
Tsunashima R, Naoi Y, Kagara N, Shimoda M,
Shimomura A, Maruyama N, Shimazu K, Kim SJ and Noguchi S:
Construction of multi-gene classifier for prediction of response to
and prognosis after neoadjuvant chemotherapy for estrogen receptor
positive breast cancers. Cancer Lett. 365:166–173. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
D'Alfonso TM, van Laar RK, Vahdat LT,
Hussain W, Flinchum R, Brown N, John LS and Shin SJ: BreastPRS is a
gene expression assay that stratifies intermediate-risk Oncotype DX
patients into high- or low-risk for disease recurrence. Breast
Cancer Res Treat. 139:705–715. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Musella V, Callari M, Di Buduo E, Scuro M,
Dugo M, Miodini P, Bianchini G, Paolini B, Gianni L, Daidone MG and
Cappelletti V: Use of formalin-fixed paraffin-embedded samples for
gene expression studies in breast cancer patients. PLoS One.
10:e01231942015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tsunashima R, Naoi Y, Kishi K, Baba Y,
Shimomura A, Maruyama N, Nakayama T, Shimazu K, Kim SJ, Tamaki Y
and Noguchi S: Estrogen receptor positive breast cancer identified
by 95-gene classifier as at high risk for relapse shows better
response to neoadjuvant chemotherapy. Cancer Lett. 324:42–47. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pease AM, Riba LA, Gruner RA, Tung NM and
James TA: Oncotype DX® recurrence score as a predictor
of response to neoadjuvant chemotherapy. Ann Surg Oncol.
26:366–371. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bear HD, Wan W, Robidoux A, Rubin P,
Limentani S, White RL Jr, Granfortuna J, Hopkins JO, Oldham D,
Rodriguez A and Sing AP: Using the 21-gene assay from core needle
biopsies to choose neoadjuvant therapy for breast cancer: A
multicenter trial. J Surg Oncol. 115:917–923. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chang JC, Makris A, Gutierrez MC,
Hilsenbeck SG, Hackett JR, Jeong J, Liu ML, Baker J, Clark-Langone
K, Baehner FL, et al: Gene expression patterns in formalin-fixed,
paraffin-embedded core biopsies predict docetaxel chemosensitivity
in breast cancer patients. Breast Cancer Res Treat. 108:233–240.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gianni L, Zambetti M, Clark K, Baker J,
Cronin M, Wu J, Mariani G, Rodriguez J, Carcangiu M, Watson D, et
al: Gene expression profiles in paraffin-embedded core biopsy
tissue predict response to chemotherapy in women with locally
advanced breast cancer. J Clin Oncol. 23:7265–7277. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Whitworth P, Stork-Sloots L, de Snoo FA,
Richards P, Rotkis M, Beatty J, Mislowsky A, Pellicane JV, Nguyen
B, Lee L, et al: Chemosensitivity predicted by BluePrint 80-gene
functional subtype and MammaPrint in the prospective neoadjuvant
breast registry symphony trial (NBRST). Ann Surg Oncol.
21:3261–3267. 2004. View Article : Google Scholar
|
